Search

Displaying results 4531 - 4540 of 5895 in total
  1. Drug

    Benapenem

    go.drugbank.com/drugs/DB18883
    Investigational

    Benapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (Cuti) or Acute Pyelonephritis

  2. Drug

    Minzasolmin

    go.drugbank.com/drugs/DB18961
    Investigational

    Minzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's

  3. Drug

    Recombinant human kallikrein-1

    go.drugbank.com/drugs/DB19232
    Investigational

    Recombinant human kallikrein-1 is under investigation in clinical trial NCT01845064 (A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients).

  4. Drug

    Ulevostinag

    go.drugbank.com/drugs/DB14721
    Investigational

    Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear … factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs)

    Synonyms: Guanosine, (p(r))-2'-deoxy-2'-fluoro-5'-o-((r)-hydroxymercaptophosphinyl)-p-thio-.beta.-d-arabino-adenylyl-(3'->5')-3'-deoxy-3'-fluoro-, cyclic nucleotide
  5. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC))[L30428] and aims to induce broad

  6. Drug

    Liposomal prostaglandin E1

    go.drugbank.com/drugs/DB05391
    Investigational

    Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.

  7. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  8. Drug

    MVA-SARS-2-S

    go.drugbank.com/drugs/DB16432
    Investigational

    MVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines

  9. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments … Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in

  10. Drug

    TC-2216

    go.drugbank.com/drugs/DB06044
    Investigational

    TC-2216 showed greater potency than and anti-depressant effects comparable to selective serotonin reuptake inhibitors and tricyclics, which are commonly used treatments for depression, as well as anxiety-relieving